We propose herein to consider the use of 1-diethylcarbamyl-4-methyl piperazine dihydrogen citrate (hetrazan®)1in the treatment of ascariasis in children. Only casual reference to the report of Ochsner, DeBakey and Dixon,2with its complete bibliography, will serve to impress one with the importance of ascariasis and to emphasize that ascaris infections are capable of causing serious complications in the gastrointestinal, respiratory, cardiovascular and reproductive systems. Added importance is placed on these infections when it is realized that ascariasis is the most common of the helminthic diseases. In certain areas of this country, as well as in other countries, ascariasis with its complications ranks high as one of the major medical problems in children. Numerous anthelminthic drugs have been advocated in the past for the treatment of ascariasis. The most widely used agent at the present time is hexylresorcinol. This drug is not an ideal agent for children for